
The Simplify Health Care ETF, identified by its symbol PINK, is engineered to generate significant long-term capital appreciation. It offers investors diversified exposure to pioneering and innovative companies of varying market capitalizations across crucial healthcare sub-sectors, including biotechnology, medical technology, gene therapy, and other rapidly expanding health-related industries. The fund is expertly managed by Michael Taylor, who serves as the lead portfolio manager, bringing more than two decades of specialized experience in overseeing long/short healthcare equity portfolios…
Is PINK's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

Simplify Health Care ETF has a higher expense ratio and a lower dividend yield than VanEck Pharmaceutical ETF. VanEck Pharmaceutical ETF maintains a more concentrated portfolio focused exclusively on global pharmaceutical giants.

IMAGE LINK HERE PALM BEACH, Fla., Oct. 1, 2026 /PRNewswire/ -- This Breast Cancer Awareness Month, Lilly Pulitzer is proud to support The Pink Agenda, a nonprofit committed to raising money for breast cancer research and awareness, through Petals With A Purpose, the latest chapter of the brand's ongoing Print with Purpose initiative.

The healthcare sector no longer trades at a sector discount, but valuations remain reasonable, with a forward P/E of 16–18x. And I believe Simplify Health Care ETF's concentrated, actively managed portfolio is positioned to benefit from healthcare's high return dispersion and sector-specific catalysts. Expected returns for PINK (according to my calculations) now range from 4% to 10%, contingent on catalysts like managed care premium renegotiations and FDA approvals.

The iShares Biotechnology ETF carries a lower expense ratio and significantly larger assets under management (AUM) than the Simplify Health Care ETF. The Simplify Health Care ETF provides broader exposure across healthcare sub-sectors and a higher dividend yield than the biotechnology-focused iShares fund.

VSXY's PINK is gaining momentum with five straight quarters of growth, stronger customer resonance and product-led opportunities ahead.